Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Salix gets rights to Mitsubishi Tanabe's MT1303

Executive Summary

Mitsubishi Tanabe Pharma Corp. licensed Bausch Health’s Salix Pharmaceuticals Inc. exclusive rights to develop and commercialize MT1303 (amiselimod) worldwide, excluding Japan and certain other countries in Asia in all fields, with the exception of neurology, rheumatology, and certain rare dermatology diseases where Mitsubishi Tanabe retains the rights.
Deal Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies